Compare WLFC & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLFC | MLTX |
|---|---|---|
| Founded | 1985 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 904.7M |
| IPO Year | 1996 | N/A |
| Metric | WLFC | MLTX |
|---|---|---|
| Price | $120.20 | $13.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $36.33 |
| AVG Volume (30 Days) | 57.4K | ★ 2.2M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | ★ 17.99 | N/A |
| EPS | ★ 16.70 | N/A |
| Revenue | ★ $674,381,000.00 | N/A |
| Revenue This Year | $16.17 | N/A |
| Revenue Next Year | $4.88 | N/A |
| P/E Ratio | $7.35 | ★ N/A |
| Revenue Growth | ★ 29.58 | N/A |
| 52 Week Low | $114.01 | $5.95 |
| 52 Week High | $229.67 | $62.75 |
| Indicator | WLFC | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.62 | 51.96 |
| Support Level | $114.01 | $12.43 |
| Resistance Level | $135.00 | $13.99 |
| Average True Range (ATR) | 5.23 | 0.73 |
| MACD | 0.20 | 0.75 |
| Stochastic Oscillator | 37.38 | 95.68 |
Willis Lease Finance Corp, with its subsidiaries, is a lessor and servicer of commercial aircraft and aircraft engines. The company has two reportable business segments, which include Leasing and Related Operations and Spare Parts Sales. A majority of its revenue is generated from the Leasing and Related Operations segment, which involves acquiring and leasing, under operating leases, commercial aircraft, aircraft engines, and other aircraft equipment and the selective purchase and resale of commercial aircraft engines, aircraft equipment, and other related businesses. Geographically, the company derives maximum revenue from the United States, followed by Europe, Asia-Pacific (excluding India), India, South America, Canada, Central America, and the Middle East.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.